ES2180729T3 - Tratamiento terapeutico combinado de las patologias hiperproliferantes. - Google Patents

Tratamiento terapeutico combinado de las patologias hiperproliferantes.

Info

Publication number
ES2180729T3
ES2180729T3 ES96901387T ES96901387T ES2180729T3 ES 2180729 T3 ES2180729 T3 ES 2180729T3 ES 96901387 T ES96901387 T ES 96901387T ES 96901387 T ES96901387 T ES 96901387T ES 2180729 T3 ES2180729 T3 ES 2180729T3
Authority
ES
Spain
Prior art keywords
hyperproliferant
pathologies
combined treatment
therapeutic combined
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96901387T
Other languages
English (en)
Inventor
Bruno Tocque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2180729T3 publication Critical patent/ES2180729T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA ASOCIACION MEDICAMENTOSA DE UNO O VARIOS ACIDOS NUCLEICOS QUE INHIBEN AL MENOS PARCIALMENTE LAS VIAS DE SEÑALIZACION CELULARES ONCOGENICAS Y DE UN AGENTE TERAPEUTICO ANTICANCEROSO, PARA SU UTILIZACION SIMULTANEA, SEPARADA O EXTENDIDA EN EL TIEMPO EN EL TRATAMIENTO DE LAS PATOLOGIAS HIPERPROLIFERATIVAS.
ES96901387T 1995-01-17 1996-01-12 Tratamiento terapeutico combinado de las patologias hiperproliferantes. Expired - Lifetime ES2180729T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9500436A FR2729295A1 (fr) 1995-01-17 1995-01-17 Traitement therapeutique combine des pathologies hyperproliferatives

Publications (1)

Publication Number Publication Date
ES2180729T3 true ES2180729T3 (es) 2003-02-16

Family

ID=9475169

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96901387T Expired - Lifetime ES2180729T3 (es) 1995-01-17 1996-01-12 Tratamiento terapeutico combinado de las patologias hiperproliferantes.

Country Status (21)

Country Link
US (3) US6262032B1 (es)
EP (1) EP0800399B1 (es)
JP (3) JP4580469B2 (es)
KR (1) KR100385266B1 (es)
AT (1) ATE222109T1 (es)
AU (1) AU716364B2 (es)
BR (1) BR9606969A (es)
CA (1) CA2209771C (es)
CZ (1) CZ298710B6 (es)
DE (1) DE69622989T2 (es)
DK (1) DK0800399T3 (es)
ES (1) ES2180729T3 (es)
FI (1) FI119911B (es)
FR (1) FR2729295A1 (es)
HU (1) HU229484B1 (es)
MX (1) MX9704490A (es)
NO (1) NO325418B1 (es)
PT (1) PT800399E (es)
SI (1) SI0800399T1 (es)
SK (1) SK283989B6 (es)
WO (1) WO1996022101A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
EP1641820B1 (en) * 2003-06-30 2008-05-28 Université de Lausanne Rasgap derived peptide for selectively killing cancer cells
US20080039409A1 (en) * 2003-12-24 2008-02-14 Locomogene, Inc. Method of Suppressing Cancer
WO2005061007A1 (ja) * 2003-12-24 2005-07-07 St. Marianna University School Of Medicine 癌の抑制方法
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
WO2008115478A2 (en) * 2007-03-19 2008-09-25 University Of Medicine And Dentistry Of New Jersey Method of cancer detection and treatment
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751307T2 (de) * 1986-03-28 1995-09-21 Univ Illinois Zubereitungen und verfahren für klone, die, mit mehrfacharzneimittelresistenz assoziierte, dna-sequenzen in menschlichen zellen enthalten.
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
CA2136091A1 (en) * 1992-05-20 1993-11-25 Daniel S. Martin Chemotherapeutic drug combinations
ATE195869T1 (de) * 1992-05-28 2000-09-15 Xenova Ltd Acridin carboxamide zur behandlung von krebs
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
US6348352B1 (en) * 1992-09-18 2002-02-19 Canji, Inc. Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6054467A (en) 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis

Also Published As

Publication number Publication date
CZ226297A3 (en) 1997-10-15
KR19980701449A (ko) 1998-05-15
PT800399E (pt) 2002-12-31
CA2209771C (fr) 2012-01-03
FR2729295B1 (es) 1997-02-28
HUP9802423A2 (hu) 1999-02-01
EP0800399A1 (fr) 1997-10-15
BR9606969A (pt) 1997-11-04
SK95797A3 (en) 1997-12-10
AU4542996A (en) 1996-08-07
WO1996022101A1 (fr) 1996-07-25
FR2729295A1 (fr) 1996-07-19
HUP9802423A3 (en) 2000-11-28
JP2008133291A (ja) 2008-06-12
MX9704490A (es) 1997-10-31
DE69622989D1 (de) 2002-09-19
NO973197L (no) 1997-07-09
CZ298710B6 (cs) 2008-01-02
KR100385266B1 (ko) 2005-09-07
HU229484B1 (en) 2014-01-28
SK283989B6 (sk) 2004-07-07
NO973197D0 (no) 1997-07-09
JP4580469B2 (ja) 2010-11-10
JPH10512559A (ja) 1998-12-02
FI119911B (fi) 2009-05-15
NO325418B1 (no) 2008-04-21
AU716364B2 (en) 2000-02-24
US20050209177A9 (en) 2005-09-22
DK0800399T3 (da) 2002-12-02
ATE222109T1 (de) 2002-08-15
US7884082B2 (en) 2011-02-08
CA2209771A1 (fr) 1996-07-25
JP5031921B2 (ja) 2012-09-26
US6262032B1 (en) 2001-07-17
DE69622989T2 (de) 2002-12-05
EP0800399B1 (fr) 2002-08-14
SI0800399T1 (en) 2002-12-31
US20040127437A1 (en) 2004-07-01
JP2012036201A (ja) 2012-02-23
US20010021395A1 (en) 2001-09-13
FI973023A (fi) 1997-07-16
FI973023A0 (fi) 1997-07-16

Similar Documents

Publication Publication Date Title
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
ES2077530B1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
UY26704A1 (es) Nueva composición farmacéutica
PE20020307A1 (es) Forma de dosificacion de farmaco activada por hidrogel
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
ES2137372T3 (es) Solucion antifungica para las uñas.
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
PT847757E (pt) Medicamento que compreende o gene de hgf
HN1999000045A (es) Derivados biciclicos del acido hidroxamico
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
BR0215404A (pt) processo e dispositivo para reduzir dosagem terapêutica
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
AR012193A1 (es) Nuevas combinaciones terapeuticas
ES2032955T3 (es) Sal sodica anhidra cristalina de 5-cloro-3-(2-tenoil)-2-oxindol-1-carboxamida.
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
TR200201071T2 (tr) Rar selektif retinoid antagonistleri kullanılarak anfizem tedavisi
ITMI992107A0 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo
MA26899A1 (fr) PREPARATIONS CONTENANT UN MEDICAMENT GLUCOCORTICOiDE POUR LE TRAITEMENT DES MALADIES BRONCHOPULMONAIRES.
AR003001A1 (es) Composicion farmaceutica estimuladora de la osteogenesis.
DE69612056T2 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
BR0108405A (pt) Agente de ativação de célula
CA2151476A1 (en) Use of cyclooxygenase inhibitors for the manufacture of a medicament for enhancing uterine blood perfusion
PT1049480E (pt) Agente herbaceo antiviral
NO20031650D0 (no) Nye legemidler for leversykdommer